Evaluate and Distinguish Early-Stage Dementia in a Matter of 5 Minutes with Brainalyze
Brainalyze, a pioneering healthtech company, is aiming to make a significant impact on the £100 billion worldwide spend on dementia treatment, care, and monitoring. The University of Southampton is licensing the Intellectual Property (IP) for Brainalyze, which is developing a simple finger-prick blood test for early diagnosis of dementia, including Alzheimer's disease.
The test, designed to be minimally invasive and provide rapid results, could enable earlier detection compared to current methods. Co-founder, CEO & CTO of Brainalyze, Professor Sumeet Mahajan, aspires to build a billion-dollar business and pioneer national level dementia screening programs for at-risk populations globally.
As Brainalyze progresses through the research and validation phases, they are focusing on refining the test for accuracy and reliability. Preliminary results have been promising, with early data suggesting an accuracy rate in the range of approximately 80-90% for detecting biomarkers associated with dementia. However, these figures are subject to further validation in larger, diverse clinical trials to confirm consistency and reliability.
Brainalyze has attracted venture capital and research grants to support its development efforts. They have raised several million dollars in funding, which is being used for technology refinement, clinical trials, and regulatory approval processes. Recently, Brainalyze secured a £1.2 million research grant for further clinical validation of their proprietary technology.
Currently, Brainalyze is launching their initial fundraising round to accelerate their path to market. They are seeking MedTech and BioTech specialist investors with experience in rapidly bringing healthtech to market and scaling it globally.
For the most current and detailed updates, direct sources like Brainalyze’s official communications or recent news releases would be the best reference. You can reach out to Brainalyze via their website or by emailing [email protected].
- Brainalyze, the healthcare technology company, is utilizing research in science to develop a simple blood test for early diagnosis of dementia, particularly Alzheimer's disease, with a focus on minimally invasive methods and rapid results.
- Professor Sumeet Mahajan, the co-founder, CEO, and CTO of Brainalyze, aims to create a billion-dollar business and implement national-level dementia screening programs for high-risk populations worldwide.
- Brainalyze's progress in research and validation stages involves refining the test for increased accuracy and reliability, with preliminary data showing an approximately 80-90% accuracy rate in detecting biomarkers associated with dementia.
- Brainalyze has secured significant funding through venture capital and research grants, totalling several million dollars, which are being allocated for technology refinement, clinical trials, and regulatory approval processes.
- To accelerate their journey towards the market, Brainalyze is currently launching an initial fundraising round and seeking investment from MedTech and BioTech specialists experienced in quickly scaling health technology globally.
